Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Caladrius Biosciences Q2 EPS $(0.11) Misses $(0.10) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from
byBill Haddad
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts